Announcements

  • Drugging premature termination codons can tune protein production up or down.

    Companies are targeting poison exons embedded in mRNA transcripts as a strategy to restore wild-type protein abundance and cell fitness in severe pediatric epilepsy and other genetic diseases.

  • Podcast logo of a black field with a grey old school microphone and two speech bubbles, the Nature Biotechnology logo at upper left and "From Bench to Podcast: Stories from Biotech Labs" at lower left

    On this episode, Associate Editor Cláudia Vilhena interviews Sean Johnson, the first author of a timely and great story on how to experimentally evaluate the performance of AI-generated enzymes. Sean and Cláudia discuss the timely topic of AI for protein design and the implications for future research, and also touch base on how it was to transition from academia to industry.

Nature Biotechnology is a Transformative Journal; authors can publish using the traditional publishing route OR via immediate gold Open Access.

Our Open Access option complies with funder and institutional requirements.

Advertisement

lona Nagy/Getty

Navigating the vaccines landscape

We explore the latest developments in the vaccines field, through our editorial feature and showcase of companies.
Collection

Advertisement

Nature Careers

Science jobs

Advertisement